United Therapeutics (NASDAQ:UTHR) Director Sells $178,941.75 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Jan Malcolm sold 325 shares of the stock in a transaction on Friday, July 10th. The shares were sold at an average price of $550.59, for a total transaction of $178,941.75. Following the completion of the sale, the director directly owned 450 shares of the company’s stock, valued at approximately $247,765.50. This trade represents a 41.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $547.06 on Monday. The firm’s 50-day moving average is $556.70 and its 200-day moving average is $529.55. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The company has a market cap of $23.22 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 1.80 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the business posted $6.63 EPS. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. Equities analysts predict that United Therapeutics Corporation will post 26.63 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently modified their holdings of the stock. Handelsbanken Fonder AB lifted its position in shares of United Therapeutics by 4.1% during the 2nd quarter. Handelsbanken Fonder AB now owns 13,120 shares of the biotechnology company’s stock worth $7,109,000 after buying an additional 520 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab boosted its stake in United Therapeutics by 7.4% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 11,058 shares of the biotechnology company’s stock valued at $5,992,000 after buying an additional 760 shares in the last quarter. Assenagon Asset Management S.A. grew its position in United Therapeutics by 79.2% in the second quarter. Assenagon Asset Management S.A. now owns 84,538 shares of the biotechnology company’s stock valued at $45,805,000 after acquiring an additional 37,355 shares during the period. GAMMA Investing LLC grew its position in United Therapeutics by 10.3% in the second quarter. GAMMA Investing LLC now owns 1,769 shares of the biotechnology company’s stock valued at $958,000 after acquiring an additional 165 shares during the period. Finally, Versant Capital Management Inc raised its stake in United Therapeutics by 93.6% during the second quarter. Versant Capital Management Inc now owns 182 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 88 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

UTHR has been the topic of several recent research reports. Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Bank of America reduced their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Ten analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $644.82.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.